» Articles » PMID: 39062006

Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma

Overview
Journal Biomedicines
Date 2024 Jul 27
PMID 39062006
Authors
Affiliations
Soon will be listed here.
Abstract

More than 800,000 people worldwide are diagnosed with HCC (hepatocellular carcinoma) each year, with approximately 700,000 deaths alone occurring in that same year. Treatment of HCC presents complex therapeutic challenges, particularly in intermediate and advanced stages. LRTs such as transarterial chemoembolization (TACE) and ablations have been the mainstay treatment for early to intermediate-stage HCC, and systemic therapies are used to treat intermediate-late-stage HCC. However, novel literature describing combining LRT with systemic therapies has shown promising results. This review explores recent advances in both liver-directed techniques for hepatocellular carcinoma, including bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies in conjunction as well as with systemic therapies, with a focus on combination therapies, patient selection, procedural technique, periprocedural management, and outcomes. Our findings suggest that LRT combined with systemic therapies is a viable strategy for improving progression-free survival and time to progression for patients with intermediate-to-late-stage HCC. However, further investigation is required to refine treatment protocols and define patient cohorts that would benefit the most.

Citing Articles

Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances.

Wu G, Bajestani N, Pracha N, Chen C, Makary M Cancers (Basel). 2024; 16(23).

PMID: 39682122 PMC: 11640160. DOI: 10.3390/cancers16233933.


Locoregional Therapies for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.

Susman S, Santoso B, Makary M Biomedicines. 2024; 12(10).

PMID: 39457538 PMC: 11504147. DOI: 10.3390/biomedicines12102226.

References
1.
Wang F, Numata K, Komiyama S, Miwa H, Sugimori K, Ogushi K . Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh Class A Liver function: A Pilot Study. Front Oncol. 2022; 12:843680. PMC: 9114706. DOI: 10.3389/fonc.2022.843680. View

2.
Song K, Lee M, Rhim H, Cha D, Chong Y, Lim H . Fusion imaging-guided radiofrequency ablation for hepatocellular carcinomas not visible on conventional ultrasound. AJR Am J Roentgenol. 2013; 201(5):1141-7. DOI: 10.2214/AJR.13.10532. View

3.
Jipa A, Makary M . Locoregional Therapies for Hepatobiliary Tumors: Contemporary Strategies and Novel Applications. Cancers (Basel). 2024; 16(7). PMC: 11010828. DOI: 10.3390/cancers16071271. View

4.
Ricke J, Klumpen H, Amthauer H, Bargellini I, Bartenstein P, De Toni E . Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019; 71(6):1164-1174. DOI: 10.1016/j.jhep.2019.08.006. View

5.
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View